United Therapeutics UTHR
$554.73 −$4.37 (-0.78%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $550.23 -0.81%
Open$561.20
Prev close$559.10
Day range$551.77 – $563.12
Volume531.8K
Market cap$23.63B
P/E (TTM)20.9
Dividend yield–
UTHR Stock News
Headlines matching United Therapeutics or the UTHR ticker, most recent first.
- Jefferies Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $704 Negative
- United Therapeutics(UTHR.US) Officer Sells US$4.57 Million in Common Stock
- United Therapeutics(UTHR.US) Officer Sells US$4.52 Million in Common Stock
- United Therapeutics(UTHR.US) Officer Sells US$4.5 Million in Common Stock
- Goldman Sachs Initiates United Therapeutics(UTHR.US) With Sell Rating, Announces Target Price $321
- Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $700
- TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $675
- H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $660
- RBC Capital Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $677 Negative
- Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $700 Negative
- RBC Capital Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $704 Positive
- Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $738
- J.P. Morgan Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $687 Positive
- Jefferies Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $714 Negative
- BofA Securities Maintains United Therapeutics(UTHR.US) With Hold Rating, Cuts Target Price to $613 Negative
No comments yet — be the first to weigh in on UTHR.
Sign in to join the discussion.